Vectans Pharma is proud to announce that the Swedish Medical Products Agency has officially granted OTC status to its Lauriad® aciclovir treatment tablet for herpes labialis, Virono® 50mg, as a one-per-episode treatment.

« I am delighted to share with our partner Navamedic ASA, the approval decision of the Swedish MPA. This is a new major step for Virono® in Northern Europe. » states Vectans Pharma’s Director of Regulatory and Industrial Affairs, Jonathan Cohen.

Following Italy, France and Finland, Sweden is the fourth country to grant OTC status upon Lauriad®Aciclovir.